1215-16-3

Upstream product

• 3069-91-8 4--acetanilid 
• 779-28-2 p-Nitroso-N,N-bis(β-chlorethyl)anilin 
• 553-27-5 aniline mustard 
• 122-80-5 N-acetyl-p-phenylenediamine 
• 2067-58-5 4-amino-N,N-bis(2-chloroethyl)aniline 
• 75-36-5 acetyl chloride 
• 100-00-5 4-chlorobenzonitrile 
• 18226-17-0 N,N-bis(2-hydroxyethyl)-4-nitroaniline 

Downstream Products

• 2067-58-5 4-amino-N,N-bis(2-chloroethyl)aniline 
• 2045-17-2 4--acetanilid 
• 2045-11-6 4--acetanilid 

Relevant academic research and scientific papers

Arylamine nitrogen mustard derivative N,N-bis(2-chloroethyl)-N'-acetyl-1,4-phenylenediamine and preparation method thereof

The invention specifically discloses a structural formula of an arylamine nitrogen mustard derivative N,N-bis(2-chloroethyl)-N'-acetyl-1,4-phenylenediamine and a preparation method of the derivative. The method comprises the following steps: preparing N,N-bis(2-chloroethyl)-1,4-phenylenediamine; filling a reactor with N,N-bis(2-chloroethyl)-1,4-phenylenediamine, dichloromethane and triethylamine, cooling in an ice-water bath, stirring, dropwise adding a mixed solution of acetyl chloride and dichloromethane into the reactor, removing the ice-water bath after dropwise adding, reacting at the room temperature for 2-14 hours, washing, drying and distilling after the reaction is completed, purifying the distilled filter cake, thereby obtaining the product. The arylamine nitrogen mustard derivative disclosed by the invention can effectively reduce the toxic or side effects of nitrogen mustard on the premise of enhancing the therapeutic index of the nitrogen mustard and has the curative effects of sterilizing and diminishing inflammation so as to reduce the risk of causing complications due to decrease in immunity after chemotherapy of a patient.